

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) An isolated nucleic acid molecule comprising a first polynucleotide that comprises ~~a nucleotide sequence chosen from:~~

(a) a ~~polynucleotide~~ nucleotide sequence encoding a polypeptide comprising amino acid sequence SEQ ID NO:215; or

(b) a ~~polynucleotide~~ nucleotide sequence comprising a nucleotide sequence complementary to the nucleotide sequence of (a),

and

a second polynucleotide that comprises a nucleotide sequence encoding a secretory leader amino acid sequence, and the secretory leader is a homologous or heterologous leader, wherein the second polynucleotide is operably linked to the first polynucleotide.

2. 5.— (Canceled)

6. (Currently Amended) The nucleic acid molecule of claim ~~[[5]]~~ 1, wherein the ~~second polynucleotide comprises a second nucleotide sequence encoding a secretory leader, and the secretory leader is a homologous or heterologous leader.~~

7. (Canceled)

8. (Currently Amended) An isolated polypeptide comprising the first-amino acid sequence of SEQ ID NO:215 operatively linked to an amino acid sequence for a polypeptide fusion partner.

9. - 12. (Canceled)

13. (Currently Amended) The polypeptide of claim 8, ~~further comprising a second amino acid sequence, wherein the second amino acid sequence is operably linked to a~~ secretory leader amino acid sequence, wherein the secretory leader is a homologous leader or a heterologous leader, ~~and the first and second amino acid sequences are operably linked.~~

14.-17. (Canceled)

18. (Original) A vector comprising the nucleic acid molecule of claim 1 and a promoter that regulates the expression of the nucleic acid molecule.

19. - 22. (Canceled)

23. (Previously presented) A recombinant host cell comprising a cell and the nucleic acid of claim 1.

24. - 29. (Canceled)

30. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~[[a]]~~the nucleic acid molecule of claim 1.

31. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~[[a]]~~the polypeptide of claim 8.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the vector of claim 18.

33. (Canceled)

34. (Currently Amended) A host cell composition comprising:

- (a) ~~[[a]]~~the recombinant host cell of claim 23; and
- (b) a pharmaceutically acceptable carrier.

35. (Withdrawn; Currently Amended) A method of producing the recombinant host cell of claim 23 comprising:

- (a) providing a vector comprising an isolated nucleic acid molecule comprising a first polynucleotide that comprises:
 - (i) a polynucleotide nucleotide sequence encoding a polypeptide comprising an amino acid sequence SEQ ID NO:215; or

- (ii) a polynucleotide nucleotide sequence comprising a nucleotide sequence complementary to the nucleotide sequence of (i); and
a second polynucleotide that comprises a nucleotide sequence encoding a secretory leader amino acid sequence, and the secretory leader is a homologous or heterologous leader, wherein the second polynucleotide is operably linked to the first polynucleotide,
and
- (b) allowing a cell to come into contact with the vector to form a recombinant host cell transfected with the nucleic acid molecule.

36. (Withdrawn; Currently Amended) A method of producing the polypeptide of claim 8 comprising:

- (a) providing an isolated nucleic acid molecule comprising a first polynucleotide that comprises a polynucleotide encoding a polypeptide comprising amino acid sequence SEQ ID NO:215, and a second polynucleotide that comprises a nucleotide sequence encoding a secretory leader amino acid sequence, and the secretory leader is a homologous or heterologous, wherein the second polynucleotide is operably linked to the first polynucleotide; and
- (b) expressing the nucleic acid molecule in an expression system to produce the polypeptide.

37. - 40. (Canceled)

41. (Original) A polypeptide produced by the method of claim 36.

42. - 80. (Canceled)

81. (New) An isolated nucleic acid molecule comprising

a first polynucleotide that comprises:

(a) a nucleotide sequence encoding a polypeptide comprising amino acid
sequence SEQ ID NO:215; or

(b) a nucleotide sequence comprising a nucleotide sequence complementary to
the nucleotide sequence of (a),

and

a second polynucleotide that comprises a nucleotide sequence encoding a polypeptide
fusion partner amino acid sequence, wherein the first and second polynucleotide
sequences are operatively linked.

82. (New) The nucleic acid molecule of claim 81, wherein the polypeptide fusion
partner is an albumin or an Fc molecule.

83. (New) The polypeptide of claim 8, wherein the polypeptide fusion partner is an
albumin or an Fc molecule.

84. (New) The polypeptide of claim 83, wherein the polypeptide fusion partner is an
albumin molecule.

85. (New) The polypeptide of claim 83, wherein the polypeptide fusion partner is an Fc molecule.

86. (New) An isolated polypeptide wherein the polypeptide amino acid sequence consists of the amino acid sequence of SEQ ID NO:215.

87. (New) An isolated nucleic acid molecule encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO:215.